Related Experiment Video
Updated: May 9, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Treating osteoporosis by targeting parathyroid hormone to bone
T Ponnapakkam1, R Katikaneni1, J Sakon2
1Pediatric Endocrinology, Children's Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY, USA.
New bone-targeting parathyroid hormone (PTH-CBD) therapy shows promise for osteoporosis treatment. Monthly injections increased bone density in rats without causing hypercalcemia, offering a potentially safer and more convenient anabolic option.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Orthopedics
Background:
- Osteoporosis presents a significant public health challenge, with current bisphosphonate treatments having limitations.
- While parathyroid hormone (PTH(1-34)) is more effective, its clinical use is restricted by side effects like hypercalcemia and tumor risk, alongside inconvenient daily injections.
- Existing long-acting PTH formulations also induce severe hypercalcemia, likely due to renal effects.
Purpose of the Study:
- To investigate the potential of a bone-targeted parathyroid hormone (PTH) delivery system, PTH-CBD, to mitigate hypercalcemia while maintaining therapeutic efficacy.
- To evaluate the safety and effectiveness of monthly PTH-CBD administration in an established animal model of osteoporosis.
Main Methods:
- Development of a novel PTH-CBD conjugate designed for targeted delivery to bone via a collagen-binding domain.
- Pharmacokinetic analysis of PTH-CBD serum clearance following subcutaneous administration.
- Assessment of spinal bone mineral density (BMD) changes and serum calcium levels in ovariectomized rats after monthly PTH-CBD treatment.
Main Results:
- PTH-CBD demonstrated rapid serum clearance within 12 hours post-administration.
- Monthly subcutaneous administration of PTH-CBD resulted in a significant 14.2% increase in spinal BMD in ovariectomized rats.
- Crucially, PTH-CBD treatment was not associated with any observable hypercalcemia.
Conclusions:
- Targeted delivery of PTH to bone using a collagen-binding domain (PTH-CBD) effectively increases bone mineral density.
- PTH-CBD represents a promising therapeutic strategy for osteoporosis, potentially combining the superior efficacy of anabolic agents with improved safety and dosing convenience.
- This bone-targeting approach may overcome the dose-limiting hypercalcemia associated with other PTH formulations, paving the way for more convenient anabolic therapies.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Skeleton and Calcium Homeostasis
Osteoclasts in Bone Remodeling
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
